{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444536904
| IUPAC_name = N-[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]docosanamide
| image = Enocitabine.png
| width = 320
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|enocitabine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]]
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 55726-47-1
| ATC_prefix = none
| ATC_suffix = 
| ATC_supplemental = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2106589
| PubChem = 71734
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9YVR68W306
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01633
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 64778
| smiles = O=C(N/C/1=N/C(=O)N(\C=C\1)[C@@H]2O[C@@H]([C@@H](O)[C@@H]2O)CO)CCCCCCCCCCCCCCCCCCCCC
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)/t25-,28-,29+,30-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = SAMRUMKYXPVKPA-VFKOLLTISA-N
<!--Chemical data-->
| chemical_formula =
| C=31 | H=55 | N=3 | O=6
| molecular_weight = 565.78 g/mol
}}

'''Enocitabine''' ([[International Nonproprietary Name|INN]], marketed under the brand name '''Sunrabin''') is a [[nucleoside]] analog used as [[chemotherapy]].

Sunrabin contains the [[emulsifier]] HCO-60, which can cause allergic reactions.<ref name="pmid12931567">{{cite journal |vauthors=Tatetsu H, Asou N, Nakamura M |title=[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine] |language=Japanese |journal=Rinsho Ketsueki |volume=44 |issue=7 |pages=471â€“3 |date=July 2003 |pmid=12931567 |doi= |url=|display-authors=etal}}</ref>

==References==
{{Reflist}}
* {{ja icon}} [http://www.ak-hcc.com/medical/product/SBA/SBAten.pdf Sunrabin]

{{Chemotherapeutic agents}}

[[Category:Antineoplastic drugs]]


{{antineoplastic-drug-stub}}